Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

741. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis

Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandara N, Hathiwala S, Smith E CRD (...) summary The authors concluded that among patients with chronic kidney disease from any cause, renin angiotensin system blockade reduced myocardial infarctions, heart failure and overall cardiovascular adverse events compared with placebo. The conclusions may need to be interpreted cautiously due to the small number of studies included in the main analyses, unexplained heterogeneity and inconsistent findings across different clinical outcomes. Authors' objectives To determine the effects of renin

2008 DARE.

742. A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases

A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases Song Z, Brassard P, Brophy J M CRD summary This review assessed use of antibiotics for the prevention of future cardiac events in patients with established cardiovascular disease. The authors concluded there was no evidence (...) to support this intervention. The conclusion reflected the results of the review accurately but, due to the limited search, publication bias and poor reporting of review methodology its reliability is unclear. Authors' objectives To assess the use of antibiotics for the prevention of future cardiac events in patients with established cardiovascular disease. Searching PubMed and the Cochrane Central Register of Controlled Trials were searched for studies published between January 1994 and April 2006

2008 DARE.

743. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model

Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Rees A, Wilkinson A, Durrington P, Chilcott (...) J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of long-term ezetimibe (EZE) monotherapy in comparison with no treatment in patients with established cardiovascular disease

2008 NHS Economic Evaluation Database.

744. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data regis

Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data regis Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs (...) using data registries Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Wilkinson A, Durrington P, Chilcott J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each

2008 NHS Economic Evaluation Database.

745. The clinical and cost-effectiveness of intensive versus standard lipid lowering with statins in the prevention of cardiovascular events amongst patients with acute coronary syndromes: a systematic review

The clinical and cost-effectiveness of intensive versus standard lipid lowering with statins in the prevention of cardiovascular events amongst patients with acute coronary syndromes: a systematic review The clinical and cost-effectiveness of intensive versus standard lipid lowering with statins in the prevention of cardiovascular events amongst patients with acute coronary syndromes: a systematic review The clinical and cost-effectiveness of intensive versus standard lipid lowering (...) with statins in the prevention of cardiovascular events amongst patients with acute coronary syndromes: a systematic review Greenheld W, Wilson J, Bayliss S, Hyde C Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Greenheld W, Wilson J, Bayliss S, Hyde C. The clinical and cost-effectiveness of intensive versus standard lipid lowering with statins in the prevention

2008 Health Technology Assessment (HTA) Database.

746. Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions

Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions The Norwegian Knowledge Centre for the Health Services Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation The Norwegian Knowledge Centre for the Health Services. Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions. Oslo: Norwegian Knowledge Centre for the Health Services (NOKC). Report number 20 - 2008. 2008 Authors' objectives To conduct a systematic review of published scientific literature on the effects of interventions for primary prevention of cardiovascular disease. This was to be used as background material

2008 Health Technology Assessment (HTA) Database.

747. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. Full Text available with Trip Pro

Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. Basic research and observational studies suggest vitamin E or vitamin C may reduce the risk of cardiovascular disease. However, few long-term trials have evaluated men at initially low risk of cardiovascular disease, and no previous trial in men has examined vitamin C alone in the prevention of cardiovascular disease.To evaluate whether long-term vitamin E or vitamin (...) C supplementation decreases the risk of major cardiovascular events among men.The Physicians' Health Study II was a randomized, double-blind, placebo-controlled factorial trial of vitamin E and vitamin C that began in 1997 and continued until its scheduled completion on August 31, 2007. There were 14,641 US male physicians enrolled, who were initially aged 50 years or older, including 754 men (5.1%) with prevalent cardiovascular disease at randomization.Individual supplements of 400 IU

2008 JAMA Controlled trial quality: predicted high

748. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?

of Cardiology 2007; 23: 467-473. Indexing Status Subject indexing assigned by NLM MeSH Adult; Age Factors; Aged; Antihypertensive Agents /economics /therapeutic use; Cardiovascular Diseases /economics /etiology /prevention & Cohort Studies; Cost of Illness; Cost-Benefit Analysis; Dyslipidemias /complications /drug therapy /economics; Economics, Pharmaceutical; Female; Health Care Costs; Health Care Surveys; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors /economics /therapeutic use; Hypertension (...) Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective? Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective? Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective? Grover S, Coupal L, Lowensteyn I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED

2008 NHS Economic Evaluation Database.

749. The impact of prevention on reducing the burden of cardiovascular disease Full Text available with Trip Pro

of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-36. Indexing Status Subject indexing assigned by NLM MeSH Adult; Aspirin /therapeutic use; Cardiovascular Diseases /economics /prevention & Clinical Trials as Topic; Cost of Illness; Costs and Cost Analysis; Diabetic Angiopathies /economics /prevention & Humans; United States; control; control AccessionNumber 22008102248 Date bibliographic record published 31/03/2009 Date abstract record published 24/06/2009 NHS (...) The impact of prevention on reducing the burden of cardiovascular disease The impact of prevention on reducing the burden of cardiovascular disease The impact of prevention on reducing the burden of cardiovascular disease Kahn R, Robertson R M, Smith R, Eddy D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

2008 NHS Economic Evaluation Database.

750. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk Full Text available with Trip Pro

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk (...) Greving J P, Buskens E, Koffijberg H, Algra A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of aspirin for the primary prevention of cardiovascular disease events in the Dutch population grouped

2008 NHS Economic Evaluation Database.

751. Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model

Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model Newman J, Grobman W A, Greenland P Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of a combination of four fixed-dose medications (simvastatin, captopril, hydrochlorothiazide, and atenolol) for the prevention of primary cardiovascular disease (CVD) in men aged over 55 years without CVD, hypertension, or dyslipidaemia

2008 NHS Economic Evaluation Database.

752. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. (Abstract)

Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. In 2005, a global goal of reducing chronic disease death rates by an additional 2% per year was established. Scaling up coverage of evidence-based interventions to prevent cardiovascular disease in high-risk individuals in low-income and middle-income countries could play a major part in reaching this goal. We aimed to estimate the number of deaths that could (...) be averted and the financial cost of scaling up, above current coverage levels, a multidrug regimen for prevention of cardiovascular disease (a statin, aspirin, and two blood-pressure-lowering medicines) in 23 such countries. Identification of individuals was limited to those already accessing health services, and treatment eligibility was based on the presence of existing cardiovascular disease or absolute risk of cardiovascular disease by use of easily measurable risk factors. Over a 10-year period

2007 Lancet

753. Prevention of secondary disease: lipid screening and cardiovascular risk.

Prevention of secondary disease: lipid screening and cardiovascular risk. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National

2007 New York State Department of Health

754. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study Full Text available with Trip Pro

Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study BACKGROUND: The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) trial has recently reported. OBJECTIVE: To assess the cost effectiveness of perindopril in stable coronary heart disease in the UK. METHODS: Clinical and resource use data were taken from the EUROPA trial. Costs included drugs (...) and hospitalisations. Health-related quality of life values were taken from published sources. A cost-effectiveness analysis is presented as a function of the risk of a primary event (non-fatal myocardial infarction, cardiac arrest or cardiovascular death) in order to identify people for whom treatment offers greatest value for money. RESULTS: The median incremental cost of perindopril for each quality-adjusted life year (QALY) gained across the heterogeneous population of EUROPA was estimated as 9700 pounds

2007 EvidenceUpdates Controlled trial quality: uncertain

755. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. Full Text available with Trip Pro

Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. To derive a new cardiovascular disease risk score (QRISK) for the United Kingdom and to validate its performance against the established Framingham cardiovascular disease algorithm and a newly developed Scottish score (ASSIGN).Prospective open cohort study using routinely collected data from general practice.UK practices contributing to the QRESEARCH database.The (...) derivation cohort consisted of 1.28 million patients, aged 35-74 years, registered at 318 practices between 1 January 1995 and 1 April 2007 and who were free of diabetes and existing cardiovascular disease. The validation cohort consisted of 0.61 million patients from 160 practices.First recorded diagnosis of cardiovascular disease (incident diagnosis between 1 January 1995 and 1 April 2007): myocardial infarction, coronary heart disease, stroke, and transient ischaemic attacks. Risk factors were age

2007 BMJ

756. Dietary glycemic index, dietary glycemic load, and cardiovascular disease in middle-aged and older Swedish men. Full Text available with Trip Pro

Dietary glycemic index, dietary glycemic load, and cardiovascular disease in middle-aged and older Swedish men. BACKGROUND: In women, dietary glycemic index (GI) and dietary glycemic load (GL) have been associated with cardiovascular disease; in men, however, the evidence for an association is weaker. OBJECTIVE: We tested the hypothesis that men consuming diets high in GI or GL have a greater risk of cardiovascular disease. DESIGN: At baseline, we assessed dietary GI and dietary GL by using (...) food-frequency questionnaires in 36 246 Swedish men aged 45-79 y without diabetes or prior cardiovascular disease. Participants were followed through inpatient, cause-of-death, and death registries from 1 January 1998 until 31 December 2003 for myocardial infarction, ischemic stroke, hemorrhagic stroke, and cardiovascular mortality and until 31 December 2005 for all-cause mortality. We used Cox models with age as the time scale to estimate relative risks adjusted for cigarette smoking, body mass

2007 EvidenceUpdates

757. Does a diagnosis of the metabolic syndrome provide additional prediction of cardiovascular disease and total mortality in the elderly? The Dubbo Study (Abstract)

Does a diagnosis of the metabolic syndrome provide additional prediction of cardiovascular disease and total mortality in the elderly? The Dubbo Study OBJECTIVE: To assess whether a diagnosis of the metabolic syndrome (MetS) improves the prediction of cardiovascular disease or total mortality beyond that already provided by conventional risk factors. DESIGN AND SETTING: A longitudinal cohort study conducted in Dubbo, New South Wales. PARTICIPANTS: 2805 men and women aged 60 years and older (...) living in the community, first assessed in 1988-1989 and followed for 16 years. MAIN OUTCOME MEASURES: Coronary heart disease (CHD) events, ischaemic stroke events, and total mortality. RESULTS: MetS was present in 31% of men and 34% of women. Crude CHD, ischaemic stroke, and total mortality rates were higher in the presence of MetS in men and women. In proportional hazards models that included conventional risk factors, but excluded variables used to define the presence of MetS, MetS

2007 EvidenceUpdates

758. Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding in acute coronary syndromes

Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding in acute coronary syndromes Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding in acute coronary syndromes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: aspirin plus warfarin decreases cardiovascular morbidity with an increase in major bleeding in acute coronary syndromes

2007 Evidence-Based Medicine

759. Role of clopidogrel in managing atherothrombotic cardiovascular disease. (Abstract)

more effective than aspirin in preventing serious vascular events. It is also associated with a favorable benefit-risk profile in patients at high risk (especially in acute coronary syndromes and after stenting). In patients at low risk (stable cardiovascular disease), however, the bleeding risk of dual therapy exceeds its potential benefit. The dose and duration of pretreatment before stenting, the optimal duration of treatment after drug-eluting stent implantation, concurrent administration (...) Role of clopidogrel in managing atherothrombotic cardiovascular disease. Aspirin is the most widely used antiplatelet agent for preventing and treating vascular events. The thienopyridine derivatives, ticlopidine and clopidogrel, are a suitable alternative in patients who are intolerant to aspirin, and clopidogrel exhibits better tolerability than ticlopidine. The available evidence from randomized trials indicates that dual therapy with clopidogrel and aspirin is modestly but significantly

2007 Annals of Internal Medicine

760. Vitamin E did not prevent cardiovascular disease and cancer in healthy women

Vitamin E did not prevent cardiovascular disease and cancer in healthy women Vitamin E did not prevent cardiovascular disease and cancer in healthy women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Vitamin E did not prevent cardiovascular disease and cancer in healthy women Article Text Therapeutics Vitamin E did not prevent cardiovascular disease and cancer in healthy women Statistics from Altmetric.com Request Permissions If you

2007 Evidence-Based Medicine